Daurismo (Glasdegib) for Leukemia | MyLeukemiaTeam

Connect with others who understand.

sign up Log in
About MyLeukemiaTeam
Powered By

Daurismo is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat acute myeloid leukemia (AML) in people 75 or older and those who cannot undergo intensive chemotherapy. Daurismo is often prescribed in combination with cytarabine. Daurismo is also referred to by its drug name, glasdegib.

Daurismo is a member of a class of drugs called hedgehog pathway inhibitors. Daurismo is believed to work by disrupting the survival of the stem cells from which leukemia cells develop.

How do I take it?
Prescribing information states that Daurismo is taken orally once daily.

Daurismo comes in tablet form.

Side effects
The FDA-approved label for Daurismo lists common side effects including fatigue, trouble breathing, rash, mouth sores, nausea, constipation, decreased appetite, changes in the sense of taste, abnormal bleeding, swelling, and low blood cell counts.

Rare but serious side effects listed for Daurismo include severe fetal harm when taken by pregnant women or exposed to pregnant women by male partners taking the drug.

For more details about this treatment, visit:

Daurismo — Pfizer

AML: Chemotherapy and Drug Therapy — Leukemia & Lymphoma Society

Continue with Facebook
Continue with Google
Lock Icon Your privacy is our priority. By continuing, you accept our Terms of use, and our Health Data and Privacy policies.
Already a Member? Log in